JP2023535832A5 - - Google Patents
Info
- Publication number
- JP2023535832A5 JP2023535832A5 JP2023506316A JP2023506316A JP2023535832A5 JP 2023535832 A5 JP2023535832 A5 JP 2023535832A5 JP 2023506316 A JP2023506316 A JP 2023506316A JP 2023506316 A JP2023506316 A JP 2023506316A JP 2023535832 A5 JP2023535832 A5 JP 2023535832A5
- Authority
- JP
- Japan
- Prior art keywords
- smn2
- sarna
- seq
- composition according
- reagents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020106200 | 2020-07-31 | ||
| CNPCT/CN2020/106200 | 2020-07-31 | ||
| PCT/CN2021/109146 WO2022022617A1 (en) | 2020-07-31 | 2021-07-29 | Combinatory treatment of sma with sarna and mrna modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023535832A JP2023535832A (ja) | 2023-08-21 |
| JP2023535832A5 true JP2023535832A5 (enExample) | 2024-08-05 |
Family
ID=80037241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506316A Pending JP2023535832A (ja) | 2020-07-31 | 2021-07-29 | Ｓａｒｎａとｍｒｎａ調節剤によるｓｍａの併用治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230287416A1 (enExample) |
| EP (1) | EP4189091A4 (enExample) |
| JP (1) | JP2023535832A (enExample) |
| KR (1) | KR20230049663A (enExample) |
| CN (1) | CN116490216A (enExample) |
| AU (1) | AU2021318560A1 (enExample) |
| CA (1) | CA3190509A1 (enExample) |
| IL (1) | IL300287A (enExample) |
| MX (1) | MX2023001349A (enExample) |
| WO (1) | WO2022022617A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022166849A1 (en) * | 2021-02-08 | 2022-08-11 | Ractigen Therapeutics | Multi-valent oligonucleotide agent and methods of use thereof |
| EP4750897A1 (en) * | 2023-07-27 | 2026-06-03 | Ractigen Therapeutics | Glycerol nucleic acid modified oligonucleotide agents and use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220084437A (ko) * | 2009-06-17 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 대상에게서 ｓｍｎ２ 스플라이싱을 조정하기 위한 조성물 및 방법 |
| US8729263B2 (en) * | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| EP3286318A2 (en) * | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
| WO2017075030A1 (en) * | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Methods and compositions for increasing smn expression |
| JP2019509272A (ja) * | 2016-02-23 | 2019-04-04 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 脊髄性筋萎縮症の治療のための併用療法 |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| US20190136192A1 (en) * | 2017-11-09 | 2019-05-09 | Cell Medicine, Inc. | Mesenchymal stem cell therapy for spinal muscular atrophy |
| CN110959042B (zh) * | 2018-04-10 | 2022-10-18 | 中美瑞康核酸技术(南通)研究院有限公司 | 一种新型小激活rna |
| JP2021534154A (ja) * | 2018-08-15 | 2021-12-09 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 脊髄性筋萎縮症のための併用療法 |
| MX2021007932A (es) * | 2018-12-29 | 2021-08-16 | Ractigen Therapeutics | Molecula oligomerica de acido nucleico y uso de esta. |
| US20200237931A1 (en) * | 2019-01-25 | 2020-07-30 | Oxford University Innovation Limited | Molecules targeting survival motor neuron 2 |
-
2021
- 2021-07-29 IL IL300287A patent/IL300287A/en unknown
- 2021-07-29 CN CN202180058670.7A patent/CN116490216A/zh active Pending
- 2021-07-29 KR KR1020237006996A patent/KR20230049663A/ko active Pending
- 2021-07-29 EP EP21850439.7A patent/EP4189091A4/en active Pending
- 2021-07-29 CA CA3190509A patent/CA3190509A1/en active Pending
- 2021-07-29 AU AU2021318560A patent/AU2021318560A1/en not_active Withdrawn
- 2021-07-29 US US18/007,497 patent/US20230287416A1/en active Pending
- 2021-07-29 JP JP2023506316A patent/JP2023535832A/ja active Pending
- 2021-07-29 MX MX2023001349A patent/MX2023001349A/es unknown
- 2021-07-29 WO PCT/CN2021/109146 patent/WO2022022617A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10369232B2 (en) | Allele selective gene editing and uses thereof | |
| JP2024502210A5 (enExample) | ||
| JP2022540446A5 (enExample) | ||
| JP2010500025A5 (enExample) | ||
| JP2025016451A5 (enExample) | ||
| JP2022185052A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| CN106460025A (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| JP6847852B2 (ja) | 癌治療のためのヒト抗原Ｒ発現のｓｉＲＮＡ阻害 | |
| TW201919654A (zh) | 用於抑制α-ENaC表現之RNAi試劑及使用方法 | |
| TW201827596A (zh) | 抑制補體b因子之表現之核酸 | |
| JP2022180437A5 (enExample) | ||
| WO2022140264A1 (en) | Rna therapeutics and methods of use thereof | |
| JP2021525531A5 (enExample) | ||
| TWI679023B (zh) | 纖維化症預防或治療劑 | |
| WO2017043370A1 (ja) | エクソソーム分泌阻害剤 | |
| WO2024187174A2 (en) | Compositions for treating cancer with kras mutations and uses thereof | |
| JP2021534796A5 (enExample) | ||
| TW201038278A (en) | Rnai molecule for thymidylate synthase and use thereof | |
| JP2024524974A5 (enExample) | ||
| WO2011065677A2 (ko) | 암 치료용 약학 조성물 | |
| JP2021527649A5 (enExample) | ||
| JP4961549B2 (ja) | アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ | |
| CN117642507A (zh) | 反向嵌合siRNA分子及其使用方法 | |
| JP2010536380A5 (enExample) |